Publications

Biobanque centrale

1.  Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data. 
   Auteurs:
   Blank-Landeshammer B, Richard VR, Mitsa G, Marques M, LeBlanc A, Kollipara L, Feldmann I, Couetoux du Tertre M, Gambaro K, McNamara S, Spatz A, Zahedi RP, Sickmann A, Batist G, Borchers CH. 
   Cancers (Basel). 2019 Dec;11(12):1907.

Biobanque cancer du sein

1.  A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR. 
   Auteurs:
   Cavallone L, Aldamry M, Lafleur J, Lan C, Gonzalez Ginestet P, Alirezaie N, Ferrario C, Aguilar-Mahecha A, Basik M. 
   Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):909-916. 
    
2.  Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program.  
   Auteurs:
   Hirukawa A, Smith HW, Zuo D, Dufour CR, Savage P, Bertos N, Johnson RM, Bui T, Bourque G, Basik M, Giguère V, Park M, Muller WJ. 
   Nat Commun. 2018 Jun 29;9(1):2547. 
    
3.  The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. 
   Auteurs:
   Goyette MA, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault MP, Johnson RM, Carmeliet P, Basik M, Gaboury L, Muller WJ, Park M, Roux PP, Gratton JP, Côté JF. 
   Cell Rep. 2018 May 1;23(5):1476-1490. 
    
4.  The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience.  
   Auteurs:
   Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodoulopoulos R, Salvucci O, Mihalcioiu C, Roy JA, Robidoux A, Marcus EA, Batist G, Basik M. 
   Mod Pathol. 2017 Nov;30(11):1567-1576. 
    
5.   A functional in vitro model of heterotypic interactions reveals a role for interferon-positive carcinoma associated fibroblasts in breast cancer.  
   Auteurs:
   Hosein AN, Livingstone J, Buchanan M, Reid JF, Hallett M, Basik M. 
   BMC Cancer. 2015 Mar 15;15:130. 
    
6.  Biopsies: next-generation biospecimens for tailoring therapy. 
   Auteurs:
   Basik M, Aguilar-Mahecha A, Rousseau C, Diaz Z, Tejpar S, Spatz A, Greenwood CM, Batist G. 
   Nat Rev Clin Oncol. 2013 Aug;10(8):437-50 
   Review. Erratum in: Nat Rev Clin Oncol. 2013 Nov;10(11):608.

Biobanque cancer gynécologique

 La liste complète des publications de la biobanque est disponible ici.

1.  Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy. 
   Auteurs:
   Octeau D, Kessous R, Klein K, Kogan L, Pelmus M, Ferenczy A, Greenwood CMT, Van Kempen LC, Salvador S, Lau S, Tonin PN, Yasmeen A, Gotlieb WH. 
   Mol Cancer Res. 2019 Sep 17. 
    
2.  Oncologic and Surgical Outcomes of Robotic Versus Open Radical Hysterectomy for Cervical Cancer. 
   Auteurs: 
   Matanes E, Abitbol J, Kessous R, Kogan L, Octeau D, Lau S, Salvador S, Gotlieb WH.
   J Obstet Gynaecol Can. 2019 Apr;41(4):450-458. 
    
3.  Impact of lower uterine segment involvement in type II endometrial cancer and the unique mutational profile of serous tumors. 
   Auteurs:
   Kogan L, Octeau D, Amajoud Z, Abitbol J, Laskov I, Ferenczy A, Pelmus M, Eisenberg N, Kessous R, Lau S, Yasmeen A, Gotlieb WH, Salvador S.
   Gynecol Oncol Rep. 2018 Mar 19;24:43-47. 
    
4.  Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. 
   Auteurs:
   Kessous R, Octeau D, Klein K, Tonin PN, Greenwood CMT, Pelmus M, Laskov I, Kogan L, Salvador S, Lau S, Yasmeen A, Gotlieb WH.
   Gynecol Oncol. 2018 Mar;148(3):553-558.
    
5.  Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. 
   Auteurs:
   Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, Yasmeen A.
   BMC Cancer. 2017 Sep 8;17(1):638.

Biobanque lymphome

1.     Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. 

Auteurs:
Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, Hudson M, Johnson NA, Baran D, Bhulaiga N, Takano T, Cailhier JF, Piccirillo CA, Miller WH. 
Nat Commun. 2019 Oct 17;10(1):4712.

2.     Alemtuzumab for immune-related myocarditis. 

Auteurs:
Esfahani K, Buhlaiga N, Thebeault P, Lapointe R, Johnson N, Miller WH Jr. 
N Engl J Med. 2019 Jun 13;380(24):2375-2376

3.     Cell of Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus: Molecular and Clinical Factors Associated with Survival. 

Auteurs:
Tessier-Cloutier B, Twa DD, Baecklund E, Gascoyne R, Johnson NA, Backlin C, Kamen DL, Clarke AE, Ramsey-Goldman R, Lee JL, Farinha P, Bernatsky S.
Lupus Sci Med. 2019 May 4;6(1):e000324

4.     Distinct 3D Structural Patterns of Lamin A/C Expression in Hodgkin and Reed-Sternberg Cells. 

Auteurs:
Contu F, Rangel-Pozzo A, Trokajlo P, Wark L, Klewes L, Johnson NA, Petrogiannis-Haliotis T, Gartner JG, Garini Y, Vanni R, Knecht H, Mai S. 
Cancers (Basel). 2018 Aug 24;10(9).

5.     The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. 

Auteurs:
Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, Riazalhosseini Y, Hébert J, Gavino C, Vinh DC, Petrogiannis-Haliotis T, Dmitrienko S, Mann KK, Morin RD, Johnson NA. 
Leuk Lymphoma. 2018 Jan 3:1-16. 

6.     Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. 

Auteurs:
Knecht H, Johnson NA, Haliotis T, Lichtensztejn D, Mai S. Disruption of direct 3D Telomere-TRF2 interaction through two molecularly disparate mechanisms is a hallmark of primary Hodgkin and Reed-Sternberg cells. Lab Invest. 2017 Jul;97(7):772-781. Alcaide M, Yu S, Davidson J, Albuquerque M, Bushell K, Fornika D, Arthur S, Grande BM, McNamara S, Tertre MCD, Batist G, Huntsman DG, Cavallone L, Aguilar A, Basik M, Johnson NA, Deyell RJ, Rassekh SR, Morin RD. 
Sci Rep. 2017 Sep 5;7(1):10574. 

7.     Multiplex droplet digital PCR quantification of recurrent somatic mutations in Diffuse Large B-Cell and Follicular Lymphoma. 

Auteurs:
Alcaide M, Yu S, Bushell K, Fornika D, Nielsen JS, Nelson BH, Mann KK, Assouline S, Johnson NA, Morin RD. 
Clin Chem. 2016 Sep;62(9):1238-47. 

8.     Genetic landscapes of relapsed and refractory diffuse large B cell lymphomas. 

Auteurs:
Morin RD, Assouline SE, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Holm Nielsen T, Petrogiannis-Haliotis T, Crump M, Tosikyan A, Grande BM, Macdonald D, Rousseau C, Bayat M, Sesques P, Froment R, Albuquerque M, Monczak Y, Klein-Oros K, Greenwood C, Riazalhosseini Y, Arseneault M, Camlioglu E, Constantin AM, Pan-Hammarström Q, Peng RJ, Mann KK, Johnson NA. 
Clin Cancer Res. 2016 May 1;22(9):2290-300. 

9.     Monitoring response and resistance to the novel arsenical darinaparsin in an AML patient. 

Auteurs:
Nielsen TH, Johnson NA, Garnier N, Kwan S, Yao L, Cocolakis E, Hébert J, Morgan RA, Paquet E, Callahan KP, Jordan CT, Assouline S, Miller WH, Mann KK. 
Front Pharmacol. 2013;4:9. 

Montréal biobanque événements indésirables liés au déficit immunitaire (MIRAE)

1.  Moving towards personalized treatments of immune-related adverse events

Auteurs:
Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH, Calabrese L.
Nat Rev Clin Oncol. 2020 Apr 3.

2.     Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. 

Auteurs:
Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, Hudson M, Johnson NA, Baran D, Bhulaiga N, Takano T, Cailhier JF, Piccirillo CA, Miller WH.
Nat Commun. 2019 Oct 17;10(1):4712. 

3.     Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. 

Auteurs:
Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr.
N Engl J Med. 2019 Jun 13;380(24):2375-2376.

Programme de génomique clinique de McGill (McG)

À venir.

Dernière mise à jour: 2020-01-10